Add to ORKGDarbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patient
Background. Anaemia is aggravated by the coexistence of chronic kidney disease (CKD) in patients inf...
Aim: Darbepoetin alfa, an erythropoiesis-stimulating protein, has a longer serum half-life than reco...
Abstract. Recombinant human erythropoietin (R-Hu-EPO) was given to stable, long-term haemodialysis p...
Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis...
Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose fre...
Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated ...
Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated ...
Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated ...
Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-ep...
BACKGROUND/PURPOSE: Darbepoetin alfa can be administered less frequently than recombinant human eryt...
stimulating agent (ESA) that is designed to specifically stimulate the erythropoietin receptor. This...
Darbepoetin alfa can be administered less frequently than recombinant human erythropoietin (r-HuEPO)...
Background/PurposeDarbepoetin alfa can be administered less frequently than recombinant human erythr...
Abstract. In eleven patients with uraemia on intermittent haemodialysis treatment, recombinant human...
stimulating agent (ESA) that is designed to specifically stimulate the erythropoietin receptor. This...
Background. Anaemia is aggravated by the coexistence of chronic kidney disease (CKD) in patients inf...
Aim: Darbepoetin alfa, an erythropoiesis-stimulating protein, has a longer serum half-life than reco...
Abstract. Recombinant human erythropoietin (R-Hu-EPO) was given to stable, long-term haemodialysis p...
Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis...
Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose fre...
Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated ...
Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated ...
Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated ...
Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-ep...
BACKGROUND/PURPOSE: Darbepoetin alfa can be administered less frequently than recombinant human eryt...
stimulating agent (ESA) that is designed to specifically stimulate the erythropoietin receptor. This...
Darbepoetin alfa can be administered less frequently than recombinant human erythropoietin (r-HuEPO)...
Background/PurposeDarbepoetin alfa can be administered less frequently than recombinant human erythr...
Abstract. In eleven patients with uraemia on intermittent haemodialysis treatment, recombinant human...
stimulating agent (ESA) that is designed to specifically stimulate the erythropoietin receptor. This...
Background. Anaemia is aggravated by the coexistence of chronic kidney disease (CKD) in patients inf...
Aim: Darbepoetin alfa, an erythropoiesis-stimulating protein, has a longer serum half-life than reco...
Abstract. Recombinant human erythropoietin (R-Hu-EPO) was given to stable, long-term haemodialysis p...